• Neurocrine Biosciences named Eiry W. Roberts as chief medical officer, effective immediately.
• Sanjay Keswani will leave the company under a mutual agreement.
• Roberts previously served as chief medical officer from 2018 to 2025, most recently acting as a strategic advisor.
• She spent 26 years at Eli Lilly, including as vice president of research and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609281605PR_NEWS_USPR_____LA58413) on September 28, 2026, and is solely responsible for the information contained therein.